<DOC>
	<DOCNO>NCT00878709</DOCNO>
	<brief_summary>The purpose study investigate whether neratinib reduce risk recurrence previously diagnose HER-2 positive breast cancer adjuvant treatment trastuzumab .</brief_summary>
	<brief_title>Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Stage II IIIC HER2/erbB2 positive breast cancer node positive disease . Been treat early breast cancer standard care duration trastuzumab . Could treat neoadjuvantly reach pCR . Positive clinical radiologic assessment local regional recurrence disease time study entry . History heart disease . QTc interval &gt; 0.45 second History gastrointestinal disease diarrhea major symptom .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HER-2/erbB-2 positive breast cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>neratinib</keyword>
	<keyword>HKI-272</keyword>
</DOC>